Abstract
Multiple myeloma (MM) is the second most common hematologic malignancy worldwide and till date cure for multiple myeloma has not been achieved with chemotherapy alone. Thus, the development of new effective anti-cancer targets to treat both early and advanced MM seems to be an attractive perspective. One major step for development of the cancer therapeutics is to build a comprehensive mol…